The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.07 billion.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.01 USD | -0.60% | +0.72% | -2.71% |
May. 09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
(Reuters) - Pfizer on Wednesday forecast 2024 revenue that was below Wall Street expectations, and increased its target for cost cuts by $500 million.
The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.07 billion.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
1st Jan change | Capi. | |
---|---|---|
-2.71% | 159B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |